Droperidol Sintetica 0.5 mg/ ml Noruega - norueguês - Statens legemiddelverk

droperidol sintetica 0.5 mg/ ml

sintetica gmbh - droperidol - injeksjonsvæske, oppløsning - 0.5 mg/ ml

Paralgin Forte 400 mg / 30 mg Noruega - norueguês - Statens legemiddelverk

paralgin forte 400 mg / 30 mg

karo pharma as - paracetamol / kodeinfosfatsesquihydrat - tablett - 400 mg / 30 mg

Paralgin Forte 400 mg / 30 mg Noruega - norueguês - Statens legemiddelverk

paralgin forte 400 mg / 30 mg

karo pharma as - paracetamol / kodeinfosfatsesquihydrat - stikkpille - 400 mg / 30 mg

Paralgin Major 800 mg / 60 mg Noruega - norueguês - Statens legemiddelverk

paralgin major 800 mg / 60 mg

karo pharma as - paracetamol / kodeinfosfatsesquihydrat - stikkpille - 800 mg / 60 mg

Citalopram Vitabalans 20 mg Noruega - norueguês - Statens legemiddelverk

citalopram vitabalans 20 mg

vitabalans oy - citalopramhydrobromid - tablett, filmdrasjert - 20 mg

Citalopram Vitabalans 40 mg Noruega - norueguês - Statens legemiddelverk

citalopram vitabalans 40 mg

vitabalans oy - citalopramhydrobromid - tablett, filmdrasjert - 40 mg

Rydapt União Europeia - norueguês - EMA (European Medicines Agency)

rydapt

novartis europharm ltd - midostaurin - leukemia, myeloid, acute; mastocytosis - antineoplastiske midler - rydapt er angitt:i kombinasjon med standard daunorubicin og cytarabine induksjon og høy dose cytarabine konsolidering kjemoterapi, og for pasienter i komplett respons etterfulgt av rydapt enkelt agent vedlikehold terapi, for voksne pasienter med nylig diagnostisert med akutt myelogen leukemi (aml) som er flt3 mutasjonspositive (se kapittel 4. 2);som monoterapi for behandling av voksne pasienter med aggressiv systemiske mastocytosis (asm), og systemiske mastocytosis med tilhørende haematological neoplasm (sm ahn), eller mast celle leukemi (mcl).

Firdapse (previously Zenas) União Europeia - norueguês - EMA (European Medicines Agency)

firdapse (previously zenas)

serb sa - amifampridine - lambert-eaton myasthenisk syndrom - andre nervesystemet narkotika - symptomatisk behandling av lambert-eaton myasthenisk syndrom (lems) hos voksne.

Imbruvica União Europeia - norueguês - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Cipralex 10 mg Noruega - norueguês - Statens legemiddelverk

cipralex 10 mg

h. lundbeck a/s - escitalopramoksalat - tablett, filmdrasjert - 10 mg